Sai Life Sciences files draft papers for nearly Rs 5,000 crore IPO
The company plans to raise funds through an offer of equity shares (face value Re 1 each) through initial public offerings. The offer comprises a fresh issue of equity shares, aggregating up to Rs 800 crore and an offer for sale (OFS) of up to 61,...
By Viswanath Pilla, ET Bureau | Updated:
BCCL - Non Copyright
Private equity (PE) firm TPG-backed Sai Life Sciences announced the filing of a draft red herring prospectus (DRHP) for its proposed Rs 5,000 crore IPO on Monday.
The company plans to raise funds through an offer of equity shares (face value Re 1 each) through initial public offerings. The offer comprises a fresh issue of equity shares, aggregating up to Rs 800 crore and an offer for sale (OFS) of up to 61,573,120 equity shares by selling shareholders.
Sai Life Sciences proposes to utilize Rs 600 crore of the net proceeds from fresh issue towards repayment of debt and the remaining for general corporate purposes
Hyderabad-based Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.
During FY24, the company served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies, across regulated markets, including the US, the UK, Europe and Japan.
Kotak Mahindra Capital Company Limited, IIFL Securities Limited, Jefferies India Private Limited and Morgan Stanley India Company Private Limited are the Book Running Lead Managers to the issue.
The company plans to raise funds through an offer of equity shares (face value Re 1 each) through initial public offerings. The offer comprises a fresh issue of equity shares, aggregating up to Rs 800 crore and an offer for sale (OFS) of up to 61,573,120 equity shares by selling shareholders.
Sai Life Sciences proposes to utilize Rs 600 crore of the net proceeds from fresh issue towards repayment of debt and the remaining for general corporate purposes
Hyderabad-based Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.
During FY24, the company served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies, across regulated markets, including the US, the UK, Europe and Japan.
Kotak Mahindra Capital Company Limited, IIFL Securities Limited, Jefferies India Private Limited and Morgan Stanley India Company Private Limited are the Book Running Lead Managers to the issue.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
